Ping-Chih Hsu

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 34

Top Topics

Chronic Obstructive Pulmonary Disease

Epidermal Growth Factor Receptor

Brain Metastases

Top Venues

Thoracic cancer

Clinics and practice

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC. Therapeutic advances in medical oncology 16 (2024)
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC. Therapeutic advances in medical oncology 16 (2024)
Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, Li-Chung Chiu, Chiung-Hsin Chang, Ping-Chi Liu, Chiao-En Wu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Yu-Ching Lin, Cheng-Ta Yang, How-Wen Ko
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Vaccines 12 (5) (2024)
Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, How-Wen Ko, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Cheng-Ta Yang
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic cancer 15 (7) (2024)
Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, How-Wen Ko, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Cheng-Ta Yang
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic cancer 15 (7) (2024)
Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, Li-Chung Chiu, Chiung-Hsin Chang, Ping-Chi Liu, Chiao-En Wu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Yu-Ching Lin, Cheng-Ta Yang, How-Wen Ko
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Vaccines 12 (5) (2024)
Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, How-Wen Ko, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Cheng-Ta Yang
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic cancer 15 (7) (2024)
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, How-Wen Ko, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Cheng-Ta Yang
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic cancer (2024)
Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang
Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. Clinics and practice 13 (1) (2023)
Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang
Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. Clinics and practice 13 (1) (2023)
Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang
Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. Clinics and practice 13 (1) (2023)
Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang
Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. Clinics and practice 13 (1) (2023)
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Allen Chung-Cheng Huang, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic advances in medical oncology 14 (2022)
Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Chiao-En Wu
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations. Therapeutic advances in respiratory disease 16 (2022)
Ping-Chih Hsu, Jhy-Ming Li, Cheng-Ta Yang
Forced Overexpression of Signal Transducer and Activator of Transcription 3 (STAT3) Activates Yes-Associated Protein (YAP) Expression and Increases the Invasion and Proliferation Abilities of Small Cell Lung Cancer (SCLC) Cells. Biomedicines 10 (7) (2022)
Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Cheng-Ta Yang
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers 14 (2) (2022)
Ming-Ru Lin, Po-Jui Chang, Ping-Chih Hsu, Chun-Sui Lin, Cheng-Hsun Chiu, Chih-Jung Chen
Comparison of Efficacy of 2% Chlorhexidine Gluconate-Alcohol and 10% Povidone-Iodine-Alcohol against Catheter-Related Bloodstream Infections and Bacterial Colonization at Central Venous Catheter Insertion Sites: A Prospective, Single-Center, Open-Label, Crossover Study. Journal of clinical medicine 11 (8) (2022)
Yan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Ping-Chih Hsu, Chiao-En Wu
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. Cancers 14 (20) (2022)
Chin-Chou Wang, Li-Chung Chiu, Pi-Hung Tung, Scott Chih-Hsi Kuo, Chia-Hsun Chu, Allen Chung-Cheng Huang, Chih-Liang Wang, Chih-Hung Chen, Cheng-Ta Yang, Ping-Chih Hsu
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. Oncology and therapy 9 (2) (2021)
Chin-Chou Wang, Li-Chung Chiu, Jia-Shiuan Ju, Yu-Ching Lin, Yueh-Fu Fang, Cheng-Ta Yang, Ping-Chih Hsu
Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines 9 (10) (2021)
Li-Chung Chiu, Ping-Chih Hsu, Tzung-Hai Yen, Allen Chung-Cheng Huang, Yueh-Fu Fang, Yu-Lun Lo, Shu-Min Lin, Cheng-Ta Yang, Chung-Shu Lee
Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. Medicina (Kaunas, Lithuania) 57 (11) (2021)
Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Allen Chung-Cheng Huang, Cheng-Ta Yang, Ping-Chih Hsu
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines 9 (7) (2021)
Chia-Hsun Chu, Tzu-Hsuan Chiu, Chin-Chou Wang, Wen-Chen Chang, Allen Chung-Cheng Huang, Chien-Ying Liu, Chih-Liang Wang, Ho-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yi-Ke Guo, Allen Chung-Cheng Huang, Cheng-Ta Yang
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Thoracic cancer 11 (6) (2020)
Ping-Chih Hsu, Cheng-Ta Yang, David M Jablons, Liang You
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers 12 (6) (2020)
Ping-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, Scott Chih-Hsi Kuo, Chia-Hsun Chu, Pi-Hung Tung, Allen Chung-Cheng Huang, Chih-Liang Wang, Li-Chung Chiu, Yueh-Fu Fang, Cheng-Ta Yang
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals (Basel, Switzerland) 13 (11) (2020)
Ping-Chih Hsu, John Wen-Chang Chang, Chun-Chieh Wang, Chen-Te Wu, Yu-Ching Lin, Chih-Liang Wang, Tin-Yu Lin, Shih-Hong Li, Yi-Chen Wu, Allen Chung-Cheng Huang, Cheng-Ta Yang, Chien-Ying Liu, Chih-Hung Chen
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study. Thoracic cancer 10 (8) (2019)
Ping-Chih Hsu, David M Jablons, Cheng-Ta Yang, Liang You
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International journal of molecular sciences 20 (15) (2019)
Shih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, Wen-Chen Chang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yi-Ke Guo, Allen Chung-Cheng Huang, Cheng-Ta Yang
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thoracic cancer 10 (12) (2019)
Cheng-Ta Yang, Ping-Chih Hsu, Shu-Er Chow
Downregulation of lumican enhanced mitotic defects and aneuploidy in lung cancer cells. Cell cycle (Georgetown, Tex.) 19 (1) (2019)
Ping-Chih Hsu, Jinbai Miao, Yu-Cheng Wang, Wen-Qian Zhang, Yi-Lin Yang, Chih-Wei Wang, Cheng-Ta Yang, Zhen Huang, Joanna You, Zhidong Xu, David M Jablons, Liang You
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. Journal of cellular and molecular medicine 22 (6) (2018)
Ping-Chih Hsu, Cheng-Ta Yang, David M Jablons, Liang You
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines 6 (4) (2018)
Ping-Chih Hsu, Jinbai Miao, Zhen Huang, Yi-Lin Yang, Zhidong Xu, Joanna You, Yu-Yuan Dai, Che-Chung Yeh, Geraldine Chan, Shu Liu, Anatoly Urisman, Cheng-Ta Yang, David M Jablons, Liang You
Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. Journal of cellular and molecular medicine 22 (6) (2018)